March 8, 2006
Biogen MS drug could be first-choice treatment-U.S. panel
GAITHERSBURG, Maryland (Reuters) - Biogen Idec and Elan's
multiple sclerosis drug Tysabri could be used as a first-choice
treatment for some patients if it returns to the market, a U.S.
advisory panel said on Wednesday.
The committee voted 7-5 in favor of Tysabri as an initial
treatment for some patients.
recommend resumed sales for the drug, which was pulled from the
market in February 2005 after three patients developed a
life-threatening brain infection and two of them died.